Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138539 · ClinicalTrials.gov registry record · Phase 4
Evaluation of an Herbal-Based De-Pigmenting System
A Phase 4 study of Melasma and Hyperpigmentation, sponsored by Sadick Research Group.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02138539 is a Phase 4 study of Melasma and Hyperpigmentation that has completed, run by Sadick Research Group. The registered enrollment target is 28 participants, below the 42-participant average among 8 other Melasma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02138539, a Phase 4 study of Melasma and Hyperpigmentation, has completed, sponsored by Sadick Research Group.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness and tolerability of an herbal de-pigmenting regimen applied to one side of the face compared with hydroquinone applied to the other side of the face in treating mottled hyperpigmentation and melasma.
Conditions Studied
Interventions
- OTHER Herbal depigmenting agent (Epionce)
- DRUG Hydroquinone
Study Locations (1)
New York
- Sadick Research Group - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138539
The ClinicalTrials.gov registry entry for NCT02138539 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 8 other Melasma trials with a reported enrollment target (33% lower). The listed sponsor is Sadick Research Group, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melasma appearing as the primary indexed condition, and to 2 interventions - of which Herbal depigmenting agent (Epionce) is the first listed.
NCT02138539 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02138539 about?
NCT02138539 is a clinical study titled "Evaluation of an Herbal-Based De-Pigmenting System". The purpose of this study is to evaluate the effectiveness and tolerability of an herbal de-pigmenting regimen applied to one side of the face compared with hydroquinone applied to the other side of the face in treating mottled hyperpigmentation and melasma.
What is the current status of trial NCT02138539?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2013-10. Estimated completion is 2014-10.
What conditions does trial NCT02138539 study?
This clinical trial studies the following conditions: Melasma, Hyperpigmentation.
What interventions are being tested in trial NCT02138539?
The interventions under investigation include: Herbal depigmenting agent (Epionce) (OTHER), Hydroquinone (DRUG).
Who is sponsoring clinical trial NCT02138539?
This trial is sponsored by Sadick Research Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02138539 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.